AR068466A1 - CYANOISOQUINOLINE - Google Patents

CYANOISOQUINOLINE

Info

Publication number
AR068466A1
AR068466A1 ARP080104039A ARP080104039A AR068466A1 AR 068466 A1 AR068466 A1 AR 068466A1 AR P080104039 A ARP080104039 A AR P080104039A AR P080104039 A ARP080104039 A AR P080104039A AR 068466 A1 AR068466 A1 AR 068466A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
compound
formula
heterocycloalkyl
Prior art date
Application number
ARP080104039A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR068466A1 publication Critical patent/AR068466A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta se refiere a compuestos que son inhibidores de la enzima PDE10A. Se proporciona una composicion farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto y un portador farmacéuticamente aceptable. La presente también proporciona un proceso para la preparacion de los compuestos de Formula 1. La presente proporciona además un método para tratar a un sujeto que sufre un trastorno neurodegenerativo, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de Formula 1. La presente también proporciona un método para tratar a un sujeto que sufre un trastorno psiquiátrico, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de Formula 1. Reivindicacion 1: Un compuesto que tiene a estructura 1 en donde: Q se selecciona de NH, O o S; R1 y R2 son independientemente alquiloC1-4; R3, R4, R5, R6 y R7 se seleccionan independientemente de: o H, alquilo C1-6, alcoxi C1-6, halogeno, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6 alquilo C1-6, hidroxicicloalquilo C1-6, cicloalcoxi C3-8, alcoxi C1-6 cicloalquilo C3-8, heterocicloalquilo, hidroxiheterocicloalquilo y alcoxi C1-6-heterocicloalquilo, en donde cada resto cicloalquilo C3-8 o heterocicloalquilo puede estar independientemente sustituido con entre uno y tres alquilo C1-6; o un grupo -NR8R9, en donde R8 y R9 se seleccionan independientemente de hidrogeno, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-8, heterocicloalquilo; o un heterociclo alifático de 6-7 miembros: representado en la formula 2: en donde n es 1 o 2 y Z es oxígeno, o NR10, en donde R10 es hidrogeno o alquilo C1-6, o una cetona, sulfona, éster, amida, éster sulfonico o sulfonamida, seleccionado del grupo 3 en donde Y es hidrogeno o alquilo C1-6 y X se selecciona de: un grupo alquilo C1-6 no sustituido o sustituido con uno o varios halogenos, -O-alquilo C1-6 no sustituido o sustituido con uno o varios halogenos, un grupo -NR11R12, donde R11 y R12 se seleccionan independientemente de hidrogeno, alquiloC1-6, haloalquilo C1-6, cicloalquilo C3-8, heterocicloalquilo, o un heterociclo alifático de 6-7 miembros: representado en la formula 4 en donde n es 1 o 2; y W es oxígeno o NR13, en donde R13 es hidrogeno o alquilo C1-6, o dos sustituyentes adyacentes seleccionados de R3, R4, R5, R6 y R7 pueden formar, junto con el anillo aromático al cual están unidos, un anillo saturado o insaturado de 5-7 miembros que contiene carbono y uno o dos heteroátomos seleccionados de N, O o S, y opcionalmente sustituido con un grupo alcoxi C1-6. Los tres sustituyentes restantes seleccionados de R3, R4, R5, R6 y R7, que no participan del anillo, se seleccionan independientemente como se menciono antes. O una sal farmacéuticamente aceptable de dicho compuesto.This refers to compounds that are inhibitors of the PDE10A enzyme. A pharmaceutical composition is provided comprising a therapeutically effective amount of a compound and a pharmaceutically acceptable carrier. The present also provides a process for the preparation of the compounds of Formula 1. The present also provides a method for treating a subject suffering from a neurodegenerative disorder, which comprises administering to the subject a therapeutically effective amount of a compound of Formula 1. The present invention also provides a method of treating a subject suffering from a psychiatric disorder, which comprises administering to the subject a therapeutically effective amount of a compound of Formula 1. Claim 1: A compound having structure 1 wherein: Q is selected from NH , O or S; R1 and R2 are independently C1-4alkyl; R3, R4, R5, R6 and R7 are independently selected from: o H, C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy C1-6 alkyl, hydroxycycloalkyl C1 -6, C3-8 cycloalkoxy, C1-6 alkoxyC3-8 cycloalkyl, heterocycloalkyl, hydroxyheterocycloalkyl and C1-6 alkoxy-heterocycloalkyl, wherein each C3-8 cycloalkyl or heterocycloalkyl moiety can be independently substituted with between one and three C1- alkyl 6; or a group -NR8R9, wherein R8 and R9 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, heterocycloalkyl; or a 6-7 membered aliphatic heterocycle: represented in formula 2: where n is 1 or 2 and Z is oxygen, or NR10, where R10 is hydrogen or C1-6 alkyl, or a ketone, sulfone, ester, amide, sulfonic ester or sulfonamide, selected from group 3 where Y is hydrogen or C1-6 alkyl and X is selected from: a C1-6 alkyl group unsubstituted or substituted with one or more halogens, -O-C1-6 alkyl not substituted or substituted with one or more halogens, a group -NR11R12, where R11 and R12 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, heterocycloalkyl, or a 6-7 aliphatic heterocycle : represented in formula 4 where n is 1 or 2; and W is oxygen or NR13, wherein R13 is hydrogen or C1-6 alkyl, or two adjacent substituents selected from R3, R4, R5, R6 and R7 can form, together with the aromatic ring to which they are attached, a saturated ring or 5-7-membered unsaturated carbon-containing and one or two heteroatoms selected from N, O or S, and optionally substituted with a C1-6 alkoxy group. The remaining three substituents selected from R3, R4, R5, R6 and R7, which do not participate in the ring, are independently selected as mentioned above. Or a pharmaceutically acceptable salt of said compound.

ARP080104039A 2007-09-19 2008-09-17 CYANOISOQUINOLINE AR068466A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701348 2007-09-19

Publications (1)

Publication Number Publication Date
AR068466A1 true AR068466A1 (en) 2009-11-18

Family

ID=40011353

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104039A AR068466A1 (en) 2007-09-19 2008-09-17 CYANOISOQUINOLINE

Country Status (8)

Country Link
EP (1) EP2203438A1 (en)
JP (1) JP2010539195A (en)
CN (1) CN101743239A (en)
AR (1) AR068466A1 (en)
CA (1) CA2691474C (en)
CL (1) CL2008002809A1 (en)
TW (1) TW200918519A (en)
WO (1) WO2009036766A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858620B2 (en) * 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
TW201215607A (en) * 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
CN103476757A (en) 2011-02-18 2013-12-25 阿勒根公司 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
RU2014123352A (en) 2011-11-09 2015-12-20 Эббви Дойчланд Гмбх Унд Ко. Кг HETEROCYCLIC CARBOXAMIDES USEFUL AS PHOSPHODESTERASE TYPE 10A INHIBITORS
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CN105102461A (en) 2012-09-17 2015-11-25 艾伯维德国有限责任两合公司 Novel inhibitor compounds of phosphodiesterase type 10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CN105209462A (en) 2013-03-14 2015-12-30 艾伯维德国有限责任两合公司 Novel inhibitor compounds of phosphodiesterase type 10A
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US20210379061A1 (en) 2018-09-28 2021-12-09 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288352A1 (en) * 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
CA2530316A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
EP1651251A4 (en) * 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp Methods for treating diabetes and related disorders using pde10a inhibitors
US20090162286A1 (en) * 2004-06-07 2009-06-25 Pfizer Inc. Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2644850A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors

Also Published As

Publication number Publication date
TW200918519A (en) 2009-05-01
JP2010539195A (en) 2010-12-16
CL2008002809A1 (en) 2009-11-27
CA2691474C (en) 2013-09-10
WO2009036766A1 (en) 2009-03-26
CA2691474A1 (en) 2009-03-26
CN101743239A (en) 2010-06-16
EP2203438A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
AR068466A1 (en) CYANOISOQUINOLINE
AR055592A1 (en) DERIVATIVES OF 2-AMINO-5-CYCLALKYL-HYDANTOINE AS MODULATORS AND / OR INHIBITORS OF BETA-SECRETASE (BACE)
AR070828A1 (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS
AR064010A1 (en) AKT ACTIVITY INHIBITORS
AR083849A1 (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
AR062900A1 (en) ISOQUINOLINE AND QUINAZOLINE DERIVATIVES USED AS QUINASA RHO INHIBITORS
AR076435A1 (en) COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES
AR039659A1 (en) HETEROARILOXI-ARIL-ESPIRO-PYRIMIDINE-2,4,6-TRIONA N-SUBSTITUTED METALOPROTEINASE METALOPROTEINASE INHIBITORS
AR075139A1 (en) BICYCLE COMPOUNDS FOR THE REDUCTION OF BETA-AMILOID PRODUCTION
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
EA200970510A1 (en) HETEROMONOCYCLIC COMPOUND AND ITS APPLICATION
AR086538A1 (en) COMPOUNDS TO REDUCE THE PRODUCTION OF B-AMYLOID
AR062409A1 (en) PHARMACEUTICAL COMPOSITION AND COMPOSITION, USED AS THERAPEUTIC AGENTS IN THE TREATMENT, PREVENTION OR IMPROVEMENT OF DISEASE OR DISORDER CHARACTERIZED BY DEPOSITS OR LEVELS OF B-AMYLOID ELEVATED OR TO INHIBIT OR ELUCIDATE THE PREPARATION OF THE BREATHING PROCESS
AR072839A1 (en) ADAMANTIL DIAMIDE DERIVATIVES AND USES OF THE SAME
AR080074A1 (en) REPLACED NAFTIRIDINS AND THEIR USE AS MEDICATIONS
AR044614A1 (en) SULFONAMIDE COMPOSITIONS THAT MODULATE THE ACTIVITY OF THE KINIOQUIN RECEIVER (CCR4)
AR066103A1 (en) DERIVATIVES OF TRIAZOLOPIRIDIN - CARBOXAMIDAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
ECSP088731A (en) DERIVATIVES OF 1,2,4,5-TETRAHIDRO-3H-BENZAZEPINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR078536A1 (en) PIRAZOL DERIVATIVES AS LEGANDS OF THE STROGEN RECEIVER
PE20091398A1 (en) BICYCLE COMPOUNDS CONTAINING ACTIVE NITROGEN IN CHRONIC PAIN CONDITIONS
PE20181017A1 (en) HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
PE20061362A1 (en) TETRAHYDRONAPHTHALINE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS AN INHIBITOR OF INFLAMMATION
AR064424A1 (en) SUBSTITUTED DERIVATIVES OF 1-OXO-FTALAZINAS and 1-OXO-PIRIDO-PIRIDAZINAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES TO PREVENT AND / OR TREAT INFLAMMATORY AND ALLERGIC DISEASES OF RESPIRATORY TRACT.
AR073043A1 (en) COMPOUNDS OF POLYSUSTITUTED AZETIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY, METABOLIC DISEASES AND OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHERS.
AR072880A1 (en) NITROGEN DERIVATIVES OF PANCRATISTATINE

Legal Events

Date Code Title Description
FB Suspension of granting procedure